|
Ìåäèêî-áèîëîãè÷åñêèé
èíôîðìàöèîííûé ïîðòàë
|
 |
äëÿ ñïåöèàëèñòîâ |
|
|
|
Vol. 16, Art. 49 (pp. 522-541) | 2015
Leiomyosarcoma of soft tissues (review)
Siniachkin M.S., Gafton G.I., Schukin V.V.
Scientific Research Institute of Oncology named after N.N. Petrov
Brief summary
Leiomyosarcoma of soft tissues - a malignant mesenchymal tumor of smooth muscle differentiation, with a high mitotic activity and intensive nature of growth. It is relatively rare tumor, which accounts for 10 to 20% of all soft tissue sarcomas. In a review article summarizes the foreign and Russian literature data of recent years devoted to the study of soft tissue leiomyosarcomas. Key words leiomyosarcoma of soft tissues, surgical treatment, metastasis, sarcoma, recurrence. (The article in PDF format. For preview need Adobe Acrobat Reader)  Open article in new window
Reference list 1. Aliev M.D. Sovremennie podhodi k lecheniu sarkom myagkih tkanei // Prakticheskaya onkologiya.–2004.–T. 5, ¹ 4.–S. 250–255. 2. Bylanov A.A., Nosov D.A., Tulyandin S.A. Aduvantnaya terapiya sarkom skeleta, sarkom myagkih tkanei i melanomi // Prakticheskaya onkologiya.–2007.–T. 8, ¹ 3.–S. 155–163. 3. Vasilev S.N., Vajenin A.V., Kotlyarov E.V. i dr. Hiryrgicheskoe i kombinirovannoe lechenie sarkom myagkih tkanei // Sibirskii onkologich. jyrn.–2001.–¹ 1.–S. 54–55. 4. Daniel–Bek K.V., Kolobyakov A.A. Zlokachestvennie opyholi koji i myagkih tkanei // M.–Medicina.–1979.–184s. 5. Kanaev S.V. Vozmojnosti lychevoi terapii sarkom myagkih tkanei // Prakticheskaya onkologiya.–2004.–T. 5, ¹ 4.–S. 256–263. 6. Macko D.E. Sovremennie predstavleniya o morfologicheskoi klassifikacii sarkom myagkih tkanei i ih prakticheskoe znachenie // Prakticheskaya onkologiya.–2013.–T. 14, ¹ 2.–S. 77–86. 7. Semenov I.I., Zaicev A.N., Krjivickii P.I., Ponomareva O.I. Metodi diagnostiki i ocenki stepeni rasprostraneniya processa pri sarkomah myagkih tkanei // Prakticheskaya onkologiya.–2013.– T. 14, ¹ 2.– S. 87–96. 8. Stolyarov V.I. Principi hiryrgicheskogo lecheniya opyholei myagkih tkanei // Tezisi mejgosydarstvennogo simpoziyma «Opyholi myagkih tkanei».–SPb.–1992.–S. 53–55. 9. Teplyakov V.V., Byharov A.V., Yrlova A.N. Oshibki v diagnostike i lechenii sarkom myagkih tkanei // Sarkomi kostei, myagkih tkanei i opyholi koji.–2012.–¹ 1.– S. 29–35. 10. Trishkin V.A., Stolyarov V.I., Kanaev S.V., Uvacheva T.P. Hiryrgicheskoe, kombinirovannoe i kompleksnoe lechenie zlokachestvennih opyholei myagkih tkanei // Metod. rekomendacii.– Leningrad.– 1980.– 21s. 11. Fedenko A.A. Targetnaya terapiya v lechenii sarkom myagkih tkanei // Prakticheskaya onkologiya.–2013.–T. 14, ¹ 2.–S. 122–126. 12. Fedenko A.A., Gorbynova V.A., Bohyan V.U. i dr. Pervii rossiiskii opit primeneniya trabektedina v lechenii disseminirovannih sarkom myagkih tkanei // Sarkomi kostei, myagkih tkanei i opyholi koji.–2011.–¹ 2.–S. 47–55. 13. Frank G.A. Problemi morfologicheskoi klassifikacii i diagnostiki opyholei myagkih tkanei // Prakticheskaya onkologiya.–2004.–T. 5, ¹ 4.–S. 231–236. 14. Chehonin V.P., Shein S.A., Korchagina A.A., Gyrina O.I. Rol VEGF v razvitii neoplasticheskogo angiogeneza // Aktyalnie voprosi onkologi.–2012.–¹ 2.–S. 23–33. 15. Amankwah E.K., Conley A.P., Reed D.R. Epidemiology and therapies for metastatic sarcoma // Clinical Epidemiology.–2013.–Vol. 5.–P. 147–162. 16. Bay J.O., Ray–Coquard I., Fayette J. et al. Docetaxel and gemcitabine combination in 133 advanced soft–tissue sarcomas: a retrospective analysis // Int. J. Cancer.–2006.–Vol. 119, ¹ 3.–P. 706–711. 17. Behranwala K.A., A'Hern R., Omar A.M., Thomas J.M. Prognosis of lymph node metastasis in soft tissue sarcoma // Ann. Surg. Oncol.–2004.–Vol. 11, ¹ 7.–P. 714–719. 18. Berrington de Gonzalez A., Kutsenko A., Rajaraman P. Sarcoma risk after radiation exposure // Clin. Sarcoma Res.– 2012.–Vol. 2, ¹ 1.– R. 2–18. 19. Billingsley K.G., Burt M.E., Jara E. et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival // Ann. Surg.–1999.–Vol. 229, ¹ 5.–P. 602–610. 20. Chugh R., Wathen J.K., Maki R.G. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model // J. Clin. Oncol.–2009.–Vol. 27, ¹ 19.–P. 3148–3153. 21. Demetri G.D., Chawla S.P., Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules // J. Clin. Oncol.–2009.–Vol. 27, ¹ 25.–P. 4188–4196. 22. Demetri G.D., Le Cesne A., Chawla S.P. et al. First–line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open–label and double–blind study // Eur. J. Cancer.–2012.–Vol. 48, ¹ 4.–P. 547–563. 23. El–Rifai W., Sarlomo–Rikala M., Knuutila S., Miettinen M. DNA copy number changes in development and progression in leiomyosarcomas of soft tissues // Am. J. Pathol.–1998.–Vol. 153, ¹ 3.–R. 985–990. 24. Evans R.A. Soft tissue sarcoma: the enigma of local recurrence // J. Surg. Oncol.–1993.–Vol. 53, ¹ 2.–P. 88–91. 25. Farshid G., Pradhan M., Goldblum J., Weiss S. Leiomyosarcoma of somatic soft tissues. A tumor of vascular origin with multivariate analysis of outcome in 42 cases // Am. J. Surg. Pathol.–2002.–Vol. 26.–P. 14–24. 26. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors // Nat. Med.–2003.–Vol. 9, ¹ 6.–R. 669–676. 27. Ferrari A., Sultan I., Huang T. et al. Soft tissue sarcoma across the age spectrum: a population–based study from the Surveillance Epidemiology and End Results database // Pediatr Blood Cancer.– 2011.– Vol. 57, ¹ 6.– P. 943–949. 28. Fong Y., Coit D. Lymph node metastasis from soft tissue sarcoma in adults // Ann. Surg.–1993.–Vol. 217, ¹ 1.– R. 72–77. 29. Gadd M.A., Casper E.S., Woodruff J.M. et al. Development and Treatment of Pulmonary Metastases in Adult Patients with Extremity Soft Tissue Sarcoma // Ann. Surg.–1993.–Vol. 218, ¹ 6.– R. 705–712. 30. Guillou L., Aurias A. Soft tissue sarcomas with complex genomic profiles // Virchows Arch.–2010.–Vol. 456, ¹ 2.–R. 201–217. 31. Gustafson P., Willén H., Baldetorp B. et al. Soft tissue leiomyosarcoma. A population–based epidemiologic and prognostic study of 48 patients, including cellular DNA content // Cancer.– 1992.–Vol. 70, ¹ 1.– P. 114–119. 32. Hornick J.L. Practical Soft Tissue Pathology // Saunders Elseiver.– Philadelphia.–2013.– 460r. 33. Jain S., Xu R., Prieto V.G., Lee P. Molecular classification of soft tissue sarcomas and its clinical applications // Int. J. Clin. Exp. Pathol.–2010.–Vol. 3, ¹ 4.–R. 416–428. 34. Kelley T.W., Borden E.C., Goldblum J.R. Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study // Appl. Immunohistochem. Mol. Morphol.–2004.–Vol. 12, ¹ 4.–R. 338–341. 35. Lamyman M., Giele H., Critchley P. et al. Local recurrence and assessment of sentinel lymph node biopsy in deep soft tissue leiomyosarcoma of the extremities // Clin. Sarcoma Res.–2011.–Vol. 1.–P. 7. 36. Le Cesne A., Antoine E., Spielmann M. et al. High–dose ifosfamide: circumvention of resistance to standard–dose ifosfamide in advanced soft tissue sarcomas // J. Clin. Oncol.–1995.–Vol. 13, ¹ 7.–P. 1600–1608. 37. Li L., Schuster I.P., Jacob R. et al. Potential benefit of hormonal therapy for non–uterine soft tissue sarcoma (STS) – a case report and literature review // Springerplus.–2013.–Vol. 2.–P. 536. 38. Maki R.G., D'Adamo D.R., Keohan M.L. et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas // J. Clin. Oncol.–2009.–Vol. 27, ¹ 19.–P. 3133–3140. 39. Mandahl N., Fletcher C.D., Dal Cin P. et al. Comparative cytogenetic study of spindle cell and pleomorphic leiomyosarcomas of soft tissues: a report from the CHAMP Study Group // Cancer Genet. Cytogenet.–2000.–Vol. 116.–P. 66–73. 40. Massi D., Beltrami G., Mela M.M. et al. Prognostic factors in soft tissue leiomyosarcoma of the extremities: a retrospective analysis of 42 cases // Eur. J. Surg. Oncol.–2004.–Vol. 30.–P. 565–572. 41. Mavrogenesis A.F., Stapropoulus N.A., Angelini A. et al. Post–Radiation Sarcomas // EEXOT.– 2012.–Vol. 63, ¹ 4.–P. 161–165. 42. Mazeron J.J., Suit H.D. Lymph nodes as sites of metastases from sarcomas of soft tissue // Cancer.–1987.–Vol. 60.–P. 1800–1808. 43. Miyajima K., Oda Y., Oshiro Y. Clinicopathological prognostic factors in soft tissue leiomyosarcoma: a multivariate analysis // Histopathology.–2002.–Vol. 40, ¹ 4.–P. 353–359. 44. Nicolas M.M., Tamboli P., Gomez J.A., Czerniak B.A. Pleomorphic and dedifferentiated leiomyosarcoma: clinicopathologic and immunohistochemical study of 41 cases // Hum. Pathol.–2010.–Vol. 41.–P. 663–671. 45. Nielsen O.S., Cummings B., O’Sullivan B. et al. Preoperative and postoperative irradiation of soft tissue sarcomas: effect of radiation field size // Int. J. Radiat. Oncol. Biol. Phys.–1991.–Vol. 21.–P. 1595–1603. 46. Nielsen O.S., Judson I., van Hoesel Q. et al. Effect of high–dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group // Eur. J. Cancer.–2000.–Vol. 36, ¹ 1.–P. 61–67. 47. Otaño–Joos M., Mechtersheimer G., Ohl S. et al. Detection of chromosomal imbalances in leiomyosarcoma by comparative genomic hybridization and interphase cytogenetics // Cytogenet. Cell Genet.–2000.–Vol. 90.–P. 86–92. 48. Pakos E.E., Goussia A.C., Tsekeris P.G. et al. Expression of vascular endothelial growth factor and its receptor, KDR/Flk–1, in soft tissue sarcomas // Anticancer Res.–2005.–Vol. 25, ¹ 5.–R. 3591–3596. 49. Pisters P.W., Leung D.H., Woodruff J. et al. Analysis of prognostic factors in 1041 patients with localised soft tissue sarcomas of the extremities // J. Clin. Oncol.–1996.–Vol. 14.–P. 1679–1689. 50. Potti A., Ganti A.K., Foster H. et al. Immunohistochemical detection of HER–2/neu, c–kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas // Anticancer Res.–2004.–Vol. 24, ¹ 1.–R. 333–337. 51. Rööser B., Gustafson P., Rydholm A. Is there no influence of local control on the rate of metastases in high-grade soft tissue sarcoma // Cancer.– 1990.–Vol.65, ¹ 8.–P. 1727-1729. 52. Rubino C., Shamsaldin A., Le M.G. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment // Breast Cancer Res. Treat.– 2005.–Vol. 89, ¹ 3.–R. 277–288. 53. Stiller C.A., Trama A., Serraino D. et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project // Eur. J. Cancer.– 2013.– Vol. 49, ¹ 3.–P. 684–95. 54. Svarvar C., Böhling T., Berlin O., et al. Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group // Cancer.– 2007.–Vol. 109, ¹ 2.–P. 282–291. 55. Toro J.R., Travis L.B., Wu H.J. et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the Surveillance, Epidemiology and End Results program, 1978–2001: an analysis of 26,758 cases // Int. J. Cancer.– 2006 .–Vol. 119, ¹ 12.–P. 2922–2930. 56. Ueda T., Yoshikawa H., Mori S. et al. Influence of local recurrence on the prognosis of soft–tissue sarcomas // J. Bone Joint Surg. Br.–1997.–Vol. 79, ¹ 4.–P. 553–557. 57. Van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft–tissue sarcoma (PALETTE): a randomised, double–blind, placebo–controlled phase 3 trial // Lancet.–2012.–Vol. 379 (9829).–R. 1879–1886. 58. Wang R., Titley J.C., Lu Y.J. et al. Loss of 13q14–q21 and gain of 5p14–pter in the progression of leiomyosarcoma // Mod. Pathol.–2003.–Vol. 16.–P. 778–785. 59. Watanabe K., Tajino T., Sekiguchi M., Suzuki T. h–Caldesmon as a Specific Marker for Smooth Muscle Tumors // Am. J. Clin. Pathol.–2000.–Vol. 113.–P. 663–668. 60. Weingrad D.N., Rosenberg S.A. Early lymphatic spread of osteogenic and soft–tissue sarcomas // Surgery.–1978.–Vol. 84.–P. 231–240. 61. Weiss S.W., Goldblum J.R. Leiomyosarcoma. In: Weiss S.W., Goldblum J.R., eds. Enzinger and Weiss’s Soft Tissue Tumors. 6th ed // Philadelphia.–2014.–P. 549–568. 62. Yang J., Du X., Chen K. et al. Genetic aberrations in soft tissue leiomyosarcoma // Cancer Lett.–2009.–Vol. 275, ¹ 1.–R. 1–8. |
|||||||||
Articles
| Ðàçìåùåíèå ðåêëàìû | |
| |
 |